Skip to main content
Premium Trial:

Request an Annual Quote

Quicker, Quicker, But Safe

The US Food and Drug Administration is working to speed it reviews of medical devices and diagnostics, Commissioner Margaret Hamburg told attendees at the AdvaMed conference, as the Boston Globe reports.

For serious conditions for which there are currently no available products, FDA, Hamburg said, is looking into an expedited approval process for devices that could help in their treatment. Still, she noted that the agency has more fast-tracking options for experimental drugs.

Mark Deem, managing partner of the medical device startup incubator the Foundry, tells the Globe that it's too late as many entrepreneurs are taking their medical device startups abroad. Products are often approved as much as three years earlier in Europe than the US.

At the same time, Lisa McGiffert, manager of the Consumers Union Safe Patient Project, notes that FDA has to weigh both speed and safety.

“It's not really a race as to who's first,” Hamburg said. “It’s to get great products to individuals."

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.